The Scientific Planning Committee will review all abstracts. All abstracts will be presented as posters. In addition, the highest scored and most relevant abstracts will be selected for an oral presentation (10–15-minute increments). All abstract submitters must be available to present at the congress between the dates of February 12-14, 2020. Official details will be sent in the notification e-mails. Authors are expected to disclose any relevant financial relationships with commercial interests.

The Scientific Planning Committee reserves the right to make the final decision concerning the form of presentation. Submission of an abstract implies that it has been approved by all listed authors. Submission of an abstract constitutes your permission for publication (e.g. congress website, program/abstract book, etc.)


To be considered, all abstracts must be submitted before the deadline (October 21st, 2019). Please note that any submitted abstract, even if accepted by the Scientific Planning Committee, will not be included in the conference program if the presenting author is not registered for the conference before December 27th, 2019.

No limit on number of abstract submissions per author or primary author.

All presenting authors are expected to disclose any relevant financial relationships with commercial interests. Please download the Faculty Disclosure Statement Form, fill out it and submit this form through the Abstract Submission online form. Please follow the instructions during the abstracts submission process to upload it correctly. Please take note that it must be uploaded as a pdf file and the name file must contain contact person name and the abstract title.


All valid abstracts prepared according to the guidelines will be considered by the program committee and assigned to appropriate oral or poster sessions. Authors whose abstracts have been accepted will be notified by e-mail by the December, 2019.


If you have difficulties in submitting your abstracts or if you need any further information, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Instructions for Abstracts

  • The abstract should enable the Scientific Planning Committee to judge the scientific merit of the paper, and the titles should clearly identify the contents of abstract. Abbreviations must not be used in the title.
  • The material in the abstract must be original. The recently published materials may be presented at the discretion of the selection committee.
  • Abstract must be submitted in English.
  • The length of each abstract is strictly limited to 300 words, (body of abstract, tables and graphics included). Title, authors and affiliations not included.
  • Indicate if you would like the abstract to be considered for oral presentation.  The final presentation type will be decided by the Scientific Planning Committee.
  • Every accepted abstract must be presented as a poster.  And then in addition, some abstracts will be selected for oral presentation
  • Please indicate the presenting author.
  • Author names and affiliations will be printed as entered in the abstract submission tool, so please make sure these are correct if you submit more than one abstract. It is also important that names are well-entered for the author index.
  • No limit on number of co-authors per submission
The body of the abstract must include the following sections, except for case reports. Please note that case reports are also encouraged.
  1. Introduction & Objectives: A sentence describing the background and a sentence describing the purpose of the study.
  2. Materials & Methods: Briefly, describe your methodology.
  3. Results: Describe your results in a logical sequence.
  4. Conclusions: Emphasise new and important aspects of the study and conclusions that are drawn from them.


Please indicate your main topic preference when submitting, (see content details below):
  • Primary Cutaneous Lymphomas: Clinical and Pathological Features
  • Basic Research - Etiology and Pathomechanisms
  • Translational and Clinical Research
  • Patient Care in Cutaneous Lymphoma

Primary Cutaneous Lymphoma
  • Mycosis fungoides
  • Sézary syndrome
  • CD30+ lymphoproliferative disorders
  • Primary cutaneous B-cell lymphomas, including follicle center lymphoma, marginal zone, and diffuse large B-cell lymphoma
  • Uncommon primary cutaneous lymphomas

Basic Research - Etiology and Pathomechanisms
  • Immunology of Cutaneous Lymphomas
  • Genomics, genetics and epigenetics
  • Molecular pathways
  • Systems biology (transcriptomics, proteomics, toponomics, metabolomics)
  • Immunology, host response and tumor microenvironment

Translational and Clinical Research
  • Biomarkers & Pathogenesis
  • New targets in the treatment of cutaneous lymphomas
  • Targeted therapies
  • Combination therapies: Prospects and problems
  • Clinical trials
  • Multinational Collaborative Studies

Patient Care in Cutaneous Lymphoma
  • Personalized medicine
  • Guidelines
  • Available therapies - new targets
  • Advanced therapies
  • Quality of life/supportive therapies
  • Difficult to treat/rare lymphomas


logoGPBlancoMarià Cubí 4 | 08006 Barcelona (SPAIN)
T. +34 932388777| F. +34 932387488
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.